US2011294892A1PendingUtilityA1

Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes

38
Assignee: OLDONI TIZIANOPriority: Sep 29, 2008Filed: Mar 25, 2011Published: Dec 1, 2011
Est. expirySep 29, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:Tiziano OldoniPaolo MascagniAlessandro RambaldiTiziano Barbui
A61P 35/02A61P 35/00A61P 7/00A61P 43/00A61P 7/02A61P 11/10A61P 11/00A61K 31/167A61K 2300/00A61K 31/18A61K 31/27A61K 31/16A61K 45/06A61K 31/00
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumor syndromes and may be from 10 to 150 mg/day/patient.

Claims

exact text as granted — not AI-modified
1 - 12 . (canceled) 
     
     
         13 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, for use in the treatment of Philadelphia-negative myeloproliferative syndromes, characterized in that the daily dosage is from 10 to 150 mg per patient. 
     
     
         14 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that it is in monohydrate form. 
     
     
         15 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that it is in monohydrate crystal form. 
     
     
         16 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that the daily dosage is from 30 to 120 mg per patient. 
     
     
         17 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that the daily dosage is from 50 to 100 mg per patient. 
     
     
         18 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that the Philadelphia-negative myeloproliferative syndrome is polycythemia vera. 
     
     
         19 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that the Philadelphia-negative myeloproliferative syndrome is essential thrombocythemia. 
     
     
         20 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13  characterized in that the Philadelphia-negative myeloproliferative syndrome is primary myelofibrosis. 
     
     
         21 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that the Philadelphia-negative myeloproliferative syndrome is secondary myelofibrosis. 
     
     
         22 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that it is not administered in combination with other active principles. 
     
     
         23 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to  claim 13 , characterized in that it is administered in combination with at least one other cytostatic active principle.

Join the waitlist — get patent alerts

Track US2011294892A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.